Literature DB >> 2531271

Vestigial mutants of Drosophila melanogaster live better in the presence of aminopterin: increased level of dihydrofolate reductase in a mutant.

J Silber1, C Bazin, A Le Menn.   

Abstract

Vestigial (vg) mutants of Drosophila melanogaster are characterized by atrophied wings. In this paper we show that: (1) aminopterin an inhibitor of dihydrofolate reductase (DHFR) and fluorodeoxyuridine (FUdR), an inhibitor of thymidylate synthetase induce nicks in the wings of wild-type flies and phenocopies of the vg mutant phenotype when vg/+ and vgB/+ flies are reared on these substances (vgB is a deficiency of the vg locus). Only thymidine and thymidylate can rescue the flies from the effect of aminopterin. We propose that the vg phenotype is due to a decrease in the dTMP pool in the wings. (2) Mutant vg strains yield more offspring on medium containing aminopterin than on normal medium. The resistance of vg larvae to the inhibitor seems specific to the gene. This is the first case of aminopterin resistance in living eucaryotes. In contrast sensitivity of the vg larvae to FUdR is observed. (3) An increase in the activity and amount of DHFR is observed in mutant strains as compared with the wild-type flies. Our data suggest that the vg+ gene is a regulatory gene acting on the DHFR gene or a structural gene involved in the same metabolic pathway.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2531271     DOI: 10.1007/bf00332412

Source DB:  PubMed          Journal:  Mol Gen Genet        ISSN: 0026-8925


  16 in total

1.  A complex genetic locus that controls of the first three steps of pyrimidine biosynthesis in Drosophila.

Authors:  J M Rawls; J W Fristrom
Journal:  Nature       Date:  1975-06-26       Impact factor: 49.962

2.  Identification of a small genetic region that encodes orotate phosphoribosylatransferase and orotidylate decarboxylase in Droxophila melanogaster.

Authors:  J M Rawls
Journal:  Mol Gen Genet       Date:  1980-04

3.  Thymidylate synthetase in mutants of Drosophila melanogaster.

Authors:  N J Carpenter
Journal:  Genetics       Date:  1973-09       Impact factor: 4.562

4.  The biochemical genetics of rudimentary mutants of Drosophila melanogaster. I. Aspartate carbamoyltransferase levels in complementing and non-complementing strains.

Authors:  S Norby
Journal:  Hereditas       Date:  1973       Impact factor: 3.271

5.  5-Fluorouracil augmentation of dihydrofolate reductase RNA containing contiguous exon and intron sequences in KB7B cells.

Authors:  C L Will; B J Dolnick
Journal:  J Biol Chem       Date:  1987-04-25       Impact factor: 5.157

6.  Isolation and partial characterization of three methotrexate-resistant phenotypes from Chinese hamster ovary cells.

Authors:  W F Flintoff; S V Davidson; L Siminovitch
Journal:  Somatic Cell Genet       Date:  1976-05

7.  Competitive protein binding assay for methotrexate.

Authors:  C E Myers; M E Lippman; H M Elliot; B A Chabner
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

8.  Pyrimidine biosynthesis in the dumpy mutants of Drosophila melanogaster.

Authors:  D H Blass; D M Hunt
Journal:  Mol Gen Genet       Date:  1980

9.  Molecular organization of the vestigial region in Drosophila melanogaster.

Authors:  J A Williams; J B Bell
Journal:  EMBO J       Date:  1988-05       Impact factor: 11.598

10.  Purification and immunochemical characterization of a dihydrofolate reductase-thymidylate synthase enzyme complex from wild-carrot cells.

Authors:  I Toth; G Lazar; H M Goodman
Journal:  EMBO J       Date:  1987-07       Impact factor: 11.598

View more
  2 in total

1.  Vestigial gene expression in Drosophila melanogaster is modulated by the dTMP pool.

Authors:  A Zider; D Flagiello; I Frouin; J Silber
Journal:  Mol Gen Genet       Date:  1996-04-24

2.  The vestigial locus of Drosophila melanogaster is involved in resistance to inhibitors of dTMP synthesis.

Authors:  J Silber; A Le Menn; S Chevillard; A Zider; S Paumard
Journal:  Mol Gen Genet       Date:  1993-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.